Evaluation of hemoglobinopathy carrier rates in Bilecik hemoglobinopathy diagnosis centre

Abstract

AimHemoglobinopathies are important public health problems with high mortality and morbidity rates. Additionally, they are amongst the most common inherited disorders in Türkiye and can be preventable with the help of premarital screening programs. The aim of the present study was to analyse the hemoglobinopathy test results in individuals who applied to the hemoglobinopathy diagnosis centre in Bilecik/Türkiye.MethodsIn our study, hemoglobinopathy test results from January 2006 to April 2017 in Bilecik Hemoglobinopathy Diagnostic Centre were evaluated retrospectively. Blood samples from individuals who applied for pre-marriage counselling and general screening were collected and hemoglobinopathies (Hb A0, A1C, A2, F, C, D, E, and S) were screened by using High Performance Liquid Chromatography (HPLC).ResultsA total of 23,676 people were included in the present study. Beta-thalassemia trait was detected in 1,317 (5.5%) and HbA2 at a level over 3.5% was detected in 1,177 (5.0%). Additionally, elevated HbF levels were over 2% of individuals (324/23,676). The positivity of hemoglobin D and HbS traits were 0.06% (15 patients) and 0.01% (two patients) respectively.ConclusionIn the present study, the positive rate of HbA2 was 4.6%. When compared, this finding was higher than the overall average rate in Türkiye. The rate is similar to those in studies from Istanbul and the Mediterranean region, but it is higher than in studies from Bursa and Kocaeli. Our results indicated that premarital hemoglobinopathy screening should be continued for all partners planning to get married and for each individual in Bilecik who may potentially have a hemoglobinopathy trait.

Keywords

Additional Information

Publisher’s Note
Bayrakol MP remains neutral with regard to jurisdictional and institutional claims.

Rights and Permissions

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). To view a copy of the license, visit https://creativecommons.org/licenses/by-nc/4.0/

View full license details →